AIMD
Ainos, Inc.
NASDAQ · USHealthcareBiotechnology
$1.59-3.64%
Price as of Jul 20, 2026
AIMD financials
Ainos, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $124.2K | $20.7K | $122.1K | $3.5M |
| Cost of revenue | $4.8M | $52.6K | $375.8K | $2.1M |
| Gross profit | -$4.7M | -$31.9K | -$253.7K | $1.4M |
| Operating expenses | $9.3M | $13.8M | $13.0M | $15.4M |
| Operating income | -$14.0M | -$13.8M | -$13.2M | -$14.0M |
| Net income | -$14.8M | -$14.9M | -$13.8M | -$14.0M |
| EBITDA | -$9.3M | -$9.4M | -$8.8M | -$9.1M |
| Basic EPS | $-3.46 | $-1.56 | $-3.36 | $-5.14 |
| Diluted EPS | $-3.46 | $-1.56 | $-3.36 | $-5.14 |
| Balance sheet | ||||
| Cash & equivalents | $417.4K | $3.9M | $1.9M | $1.9M |
| Total assets | $20.9M | $28.8M | $31.8M | $37.1M |
| Total liabilities | $13.3M | $13.3M | $7.4M | $2.5M |
| Stockholders’ equity | $7.6M | $15.5M | $24.4M | $34.6M |
| Total debt | $11.0M | $12.0M | $6.0M | $1.3M |
| Net debt | $10.6M | $8.1M | $4.1M | -$584.7K |
| Cash flow | ||||
| Operating cash flow | -$4.6M | -$5.8M | -$4.7M | -$3.0M |
| Capital expenditure | -$34.6K | -$21.3K | -$93.0K | -$633.8K |
| Free cash flow | -$4.6M | -$5.8M | -$4.8M | -$3.7M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$260 | $0.00 | -$301 | $0.00 |